Switch theme
Sign up to access all valuation multiples
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The company has three main business segments namely Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada.
2012
24K+
LTM Revenue $1.1B
LTM EBITDA $104M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Extendicare has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $104M.
In the most recent fiscal year, Extendicare achieved revenue of $1.1B and an EBITDA of $112M.
Extendicare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Extendicare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $104M | XXX | $112M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $147M | XXX | $80.3M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $53.3M | XXX | $54.3M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $123M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Extendicare's stock price is CAD 14 (or $10).
Extendicare has current market cap of CAD 1.2B (or $873M), and EV of CAD 1.4B (or $1.0B).
See Extendicare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $873M | XXX | XXX | XXX | XXX | $0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Extendicare has market cap of $873M and EV of $1.0B.
Extendicare's trades at 0.9x EV/Revenue multiple, and 8.9x EV/EBITDA.
Equity research analysts estimate Extendicare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Extendicare has a P/E ratio of 16.4x.
See valuation multiples for Extendicare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $873M | XXX | $873M | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 0.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.4x | XXX | 16.1x | XXX | XXX | XXX |
| EV/FCF | 120.4x | XXX | 13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialExtendicare's last 12 month revenue growth is 7%
Extendicare's revenue per employee in the last FY averaged $44K, while opex per employee averaged $41K for the same period.
Extendicare's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Extendicare's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Extendicare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| National Healthcare Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Addus HomeCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Amedisys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Extendicare acquired XXX companies to date.
Last acquisition by Extendicare was XXXXXXXX, XXXXX XXXXX XXXXXX . Extendicare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Extendicare founded? | Extendicare was founded in 2012. |
| Where is Extendicare headquartered? | Extendicare is headquartered in Canada. |
| How many employees does Extendicare have? | As of today, Extendicare has 24K+ employees. |
| Who is the CEO of Extendicare? | Extendicare's CEO is Dr. Michael R. Guerriere. |
| Is Extendicare publicy listed? | Yes, Extendicare is a public company listed on TSE. |
| What is the stock symbol of Extendicare? | Extendicare trades under EXE ticker. |
| When did Extendicare go public? | Extendicare went public in 1974. |
| Who are competitors of Extendicare? | Similar companies to Extendicare include e.g. National Healthcare Corp, Regis Healthcare, Maternus-Kliniken, Addus HomeCare. |
| What is the current market cap of Extendicare? | Extendicare's current market cap is $873M |
| What is the current revenue of Extendicare? | Extendicare's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Extendicare? | Extendicare revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Extendicare? | Current revenue multiple of Extendicare is 0.9x. |
| Is Extendicare profitable? | Yes, Extendicare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Extendicare? | Extendicare's last 12 months EBITDA is $104M. |
| What is Extendicare's EBITDA margin? | Extendicare's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Extendicare? | Current EBITDA multiple of Extendicare is 9.6x. |
| What is the current FCF of Extendicare? | Extendicare's last 12 months FCF is $8.3M. |
| What is Extendicare's FCF margin? | Extendicare's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Extendicare? | Current FCF multiple of Extendicare is 120.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
